Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates


Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le vendredi 13 mars 2020
Doi : 10.1016/j.therap.2020.02.010
Received : 16 September 2019 ;  accepted : 15 November 2019
The key role of oncopharmacology in therapeutic management, from common to rare cancers: A literature review

Baptiste Louveau a, b, Fanélie Jouenne a, b, Florentia Kaguelidou c, d, Alexandra Landras b, Lauriane Goldwirt a, b, Samia Mourah a, b,
a Department of pharmacology and tumor genomics, Saint-Louis hospital, Assistance publique–Hôpitaux de Paris, 75010 Paris, France 
b Université de Paris, INSERM UMRS 976, 75010 Paris, France 
c Department of pediatric pharmacology and pharmacogenetics, Robert-Debré hospital, Assistance publique–Hôpitaux de Paris, 75019 Paris, France 
d INSERM, CIC 1426, 75019 Paris, France 

Corresponding author . Department of pharmacology and tumor genomics, Saint-Louis hospital, AP–HP, 1, avenue Claude-Vellefaux, 75475 Paris cedex 10, France.Department of pharmacology and tumor genomics, Saint-Louis hospital, AP–HP1, avenue Claude-VellefauxParis cedex 1075475France

The therapeutic management of cancers has undergone considerable changes due to the emergence of genomics tools and tumor molecular deciphering. In this context, a dual pharmacological approach based on pharmacogenomic analyses and therapeutic drug monitoring is now part of the routine care in cancer management for personalized therapies. First, molecular and immune profiling of tumors allows the emergence of new pharmacological targets in common as well as in rare cancers. Second, pharmacogenomic analyses coupled to therapeutic drug monitoring guide the prescription by adjusting regimen and managing drug resistance.

The full text of this article is available in PDF format.

Keywords : Oncopharmacology, Pharmacogenomics, Therapeutic drug monitoring, Targeted therapies, Immunotherapies, Resistance

© 2020  Société française de pharmacologie et de thérapeutique@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline